Auxico Announces Results of Innovative Mettalurgical Testing
Momentum Public Relations
Press Release: February 6 2018
Auxico Resources Canada Inc. (CSE:AUAG) is pleased to announce results from innovative metallurgical testing conducted on its gold/silver properties located in the state of Sinaloa, Mexico.
Series of tests that have been conducted on gravity concentrates from the Campanillas and Aguamas properties have resulted in the recoveries of over 98% of gold and 87% of silver within the same leach. These tests have been conducted over the last year using a mix of acids composed of sulfuric acid and thioria. The extraction (less than one hour) is accelerated by the use of ultrasound technology and the process uses no external heat or pressure.
SAMPLE | Feed material % Au | Recovery % Au | Feed material % Ag | Recovery % Ag |
Aguamas | 0.01 | 98.00 | 0.08 | 88.76 |
Campanillas | 0.05 | 98.00 | 0.05 | 87.47 |
These results are highly encouraging, as the process will significantly reduce both capital and operating expenditures, while having a much smaller environmental footprint.
Qualified Person
This news release was reviewed and approved by Joel Scodnick, P.Geo., an independent consultant to Auxico, in his capacity as a Qualified Person, as defined by National Instrument 43-101.
ON BEHALF OF THE BOARD OF DIRECTORS
« signed »
Mark Billings
President, Auxico Resources Canada Inc.
mb@auxicoresources.com
Cell: +1 514 296 1641
About Auxico Resources Canada Inc.
Auxico Resources Canada Inc. (“Auxico”) in a Canadian company that was founded in 2014 and based in Montreal. Auxico is engaged in the acquisition, exploration and development of mineral properties in Mexico. The Company has a 100% interest in the Zamora Silver-Gold Property in Sinaloa, Mexico. Auxico will continue to identify and potentially acquire additional property interests and conduct exploration and evaluation of these properties to assess their potential.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in Auxico Resources, Mining
Canadian Securities Exchange to Bring Nasdaq’s Corporate Solutions to Issuers
Canadian Securities Exchange to Bring Nasdaq’s Corporate Solutions to Issuers
NEW YORK and TORONTO, Nov. 20, 2014 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq:NDAQ) today announced a new partnership with the Canadian Securities Exchange (CSE) in Toronto, to further its commitment to providing value-add Corporate Solutions offerings for listed companies in Canada. The strategic partnership will offer CSE’s issuers the full suite of Nasdaq’s market-leading Corporate Solutions products including investor services and targeting, public relations and governance solutions.
“Our solutions are built to empower companies to better inform and manage relationships with their investors, their boards and the general public,” said Paul McKeown, Senior Vice President, Corporate Solutions, Nasdaq. “This new partnership with CSE will bring our solutions and services to many new public companies listed with CSE, and expand our already significant presence in the Canadian market.”
CSE issuers will now have potential access to the Corporate Solutions suite of products including the Investor Relations desktop and mobile platforms, Advisory Services, Directors Desk and the GlobeNewswire press release distribution service. In addition to this new agreement, CSE has been a market technology customer of Nasdaq for over 10 years, operating on the X-stream trading platform.
“We are proud to be offering our listed companies some of the finest corporate services and solutions on the market through this new relationship with Nasdaq,” said Robert Cook, Senior Vice President, Market Development, Canadian Securities Exchange. “The CSE cannot emphasize enough the importance of communicating seamlessly and frequently with your key stakeholders while practicing good governance. We feel these offerings will strengthen our issuers and help them achieve their business goals.”
Nasdaq’s technology solutions are used by over 10,000 customers in 60 countries, consisting of public and private entities, exchanges, regulators and broker-dealers, and power over 100 marketplaces worldwide.
About The Canadian Securities Exchange (CSE):
The Canadian Securities Exchange is the only exchange providing trading and market information services for all securities listed in Canada. Recognized as an exchange by the Ontario Securities Commission in 2004, the CSE is designed to facilitate the capital formation process for public companies through a streamlined approach to company regulation that emphasizes disclosure and the provision of efficient secondary market trading services for investors. The exchange is home to more than 250 issues covering a broad range of industry sectors.
For more information please visit www.thecse.com and our blog at http://blog.thecse.com/.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or http://business.nasdaq.com/.
- Published in Blog
A Guide to the Canadian Securities Exchange
The Canadian Securities Exchange (CSE) was established in 2003 and is governed by CNSX Markets Incorporated. The CSE obtained stock exchange status in 2004, and was created to provide companies with a resourceful and contemporary alternative to access public capital markets in Canada. Furthermore, the CSE currently provides over 200 different structured IPs, and government bonds and equities, and continues to expand at an exponential rate in order to meet the discerning needs of its investors.
In addition, the CSE launched the first unremitting auction market in September, 2007. It was established for investors and companies who were looking to trade securities that were listed on alternative Canadian stock exchanges. Interestingly, the newly introduced auction market provides many benefits vis-à-vis other stock exchanges; including an inviting fee configuration; a low-latency environment for trading stocks, and a high capacity milieu that allows investors to use proprietary and state-of-the-art trading technologies that maximise ROI. As a result, the Canadian marketplaces’ competiveness on the worldwide marketing spectrum has risen exponentially. Moreover, it is important to note that CSE listed stocks and symbols on alternative Canadian exchanges have now been conglomerated since “Project One” was completed on December 2, 2013.
In sum, the CSE provides many benefits when compared to other stock exchanges. In addition to being an approved market maker system that boasts streamlined regulation and cost effective measures, the CSE is also a centralized auction marketplace than ensures augmented disclosure. For instance, if we were to compare the initial listing fees of the CSE to the TSX or TSX-V, one would notice that the fees incurred via the CSE are significantly lower than those of the aforementioned stock exchanges (e.g., $12,500 versus $40, 750 & $30,000). Arguably just as important, if not more so, is that the CSE does not use a transaction based modus operandi. In other words, the CSE charges a flat monthly fee of only $500, allowing investors to perform an unlimited amount of transactions at their discretion. In fact, investors can expect to spend only $18,000 worth of annual fees for listing on the CSE during the first year, followed by only $6,000 in annual fees in perpetuity afterwards. Interestingly, if one were to tabulate the initial, sustaining, and additional listing fees of the TSX-V-, TSX, and CSE, the clear advantage that the CSE provides becomes increasingly evident (e.g., $51,000/$58,950/$18,500). That is, CSE total fees are 65{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} lower than those of the TSX and 69{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} lower than the fees incurred by the TSX Venture. Ergo, the CSE is the quintessential choice for innovative companies that are looking to go public in Canada.
For more detailed information on the CSE please visit their official website.
Written by: Prakash Mylvaganam
- Published in Blog
Soros Doubles YPF Stake in Argentina’s Nascent Shale Boom
George Soros’s $28 billion family office more than doubled its stake in YPF SA, making the state-controlled oil producer its biggest U.S.-traded stock holding two years after Argentina seized control of the company.
Soros Fund Management LLC added 8.47 million shares of YPF in the second quarter, according to a filing yesterday, bringing its position to 3.5 percent of the American depositary receipts. That was worth $450 million at the end of June, making Soros the fourth-biggest holder. The stock rallied today. click here to read the full article – http://www.bloomberg.com/news/2014-08-14/soros-adds-to-ypf-trims-teva-exits-monster-in-quarter.html
- Published in Blog
CANNABIS TECHNOLOGIES ANNOUNCES SECOND THERAPY — CTI-091
CANNABIS TECHNOLOGIES ANNOUNCES SECOND THERAPY — CTI-091
Cannabis Technologies Inc. has developed a therapy containing a proprietary mixture of cannabinoids and non-cannabis-based active ingredients, CTI-091, for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression.
CTI-091 is designed to enhance retention and absorption of the key ingredients around the target site and designed for the relief of joint pain and swelling.
Currently the formulation is in preclinical stage of development. The company is also working to improve the delivery system to increase efficacy. It is expecting to go to initiate clinical phase 1 trials upon completion of these steps.
Craig Schneider, Cannabis Technologies president and chief executive officer, said: “We are extremely pleased to announce a second therapy in our expanding product pipeline. The pain and arthritis therapy takes our company to the next stage of development, reinforcing the proof of concept of our cannabinoid drug design platform. This platform is designed to effectively identify and fast-track new drug therapies. The company plans to have numerous therapies over the next 12 months within the product pipeline focusing on other areas like metabolic diseases (obesity and diabetes), orphan diseases (Huntington’s and epilepsy) as well as cancer and angiogenesis.”
Pain and arthritis market
More than 46 million Americans have arthritis or a related disease, and some experts estimate the global market for arthritis drugs brings as much as $35-billion a year in profits. The many different types of drugs used to treat arthritis and its accompanying pain include over-the-counter and prescription-only drugs, with delivery methods of injections, infusions, patches and topical agents.
We seek Safe Harbor.
- Published in Blog
New Research Shows How Marijuana Compound Can Reduce Tumor Growth In Cancer Patients
Scientists have long known that compounds derived from marijuana have some cancer fighting properties, but a recent discovery demonstrates how exactly one compound may fight tumors.
Published in the Journal of Biological Chemistry, the research reveals two previously unknown “signaling platforms” in cells that allow THC, the psychoactive ingredient in cannabis known for producing the “high” sensation, to shrink some cancerous tumors.
“THC, the major active component of marijuana, has anti-cancer properties,” Dr. Peter McCormick, a researcher from University of East Anglia in England and co-author of the study, said in a statement. “This compound is known to act through a specific family of cell receptors called cannabinoid receptors. However, it was unclear which of these receptors were responsible for the anti-tumor effects of THC.”
When the researchers applied THC to tumors induced in mice using human breast cancer cells, the interaction between two cannabinoid cell receptors — CB2 and GPR55 — were responsible for THC’s anti-tumor benefits.
“Our findings help explain some of the well-known but still poorly understood effects of THC at low and high doses on tumor growth,” McCormick added. He emphasized in an email to The Huffington Post that dosage is critical to outcome, since the wrong protocol can sometimes increase tumor growth, he said.
“So, the ideal would be either the purified THC in an effective dose provided by a health care provider to reduce the known cognitive side effects and still deliver the appropriate reduction in tumor growth, or a synthetic homolog that provides the same effects,” McCormack said. He added that the research team didn’t screen all tumors and that some types may not respond to this treatment if they do not have compatible receptors expressed.
The endocannabinoid (EC) system is a communications network in the brain and body that is involved in a number of physiological processes that affect a person’s feelings, motor skills and memory. The EC system is responsive to the body’s naturally-occurring endocannabinoids as well as the cannabinoids found in marijuana, like THC. And scientists have found that the CB2 receptor specifically is sensitive to the therapeutic properties of marijuana-based compounds.
This isn’t the first time scientists have found that marijuana can be effective at fighting cancer. Previous studies have found that THC cuts tumor growth in lung cancer in half and also prohibited the cancer from spreading. THC has also been shown to induce death in brain cancer cells.
But THC is just one of many cannabinoids found in marijuana. Others, like CBD, a non-toxic, non-psychoactive chemical compound in the cannabis plant, has also shown promise in the battle against cancer. Researchers in California found that CBD could stop metastasis in many kinds of aggressive cancer.
In the United Kingdom, a team of scientists found that six different purified cannabinoids — CBD (Cannabidiol), CBDA (Cannabidiolic acid), CBG (Cannbigerol), CBGA (Cannabigerolic acid), CBGV (Cannabigevarin) and CBGVA (Cannabigevaric acid) — showed a wide range of therapeutic qualities that “target and switch off” pathways that allow cancers to grow.
A number of studies in recent years have demonstrated the medical potential of pot beyond cancer treatment. Purified forms of cannabis has been tied to better blood sugar control, and may help slow the spread of HIV. Legalization of the plant for medical purposes may even lead to lower suicide rates.
Currently, the federal government classifies the plant as one of the “most dangerous” substances alongside heroin and LSD with “no currently accepted medical use.”
McCormack told HuffPost that the researchers are moving toward clinical trials but that it would be at least five years before those would begin.
- Published in Blog
Marijuana, now officially more expensive then gold
Shatter hash and other similar concentrates make up one of the fastest-growing facets of Colorado’s bustling marijuana industry — but shatter, which can be used for dabbing, is also still quite controversial.
Shatter can be dangerous to produce, as many have learned after blowing up their garages or hotel rooms. And it’s also an incredibly potent method of ingesting THC — hardly ideal for the inexperienced pot connoisseur.
Just how popular is shatter?
“At this point gold costs $43.50 a gram,” said Tucker Eldridge, master grower at Nature’s Herbs & Wellness, “and shatter costs $40 a gram off the shelf for medical patients. You add another 30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} tax to that, and it ends up costing more than gold.”
Shatter can sell recreationally for $60-$90 a gram, Eldridge said in the above video, by Denver Post photographer Joe Amon.
So why do some prefer shatter to flower or edibles?
“If you’re looking for something that’s significantly more potent, has significantly less adulterant plant matter, which is what combusts and produces carcinogens, then shatter hash is going to be more your cup of tea,” Eldridge said. “If you’re not looking for something that’s that potent it can be almost psychoactive.”
- Published in Blog
HIGHMARK ENTERS INTO A NON-BINDING LOI WITH A CORPORATION IN THE FINAL STAGES OF BECOMING A LICENSED PRODUCER OF MARIJUANA
Highmark Marketing Inc. has entered into a non-binding letter of intent with a corporation to acquire 51 per cent of its authorized share capital.
The Corporation is the final stages of their application to Health Canada to become a licensed producer of marijuana under the Marihuana for Medical Purposes Regulations (the “MMPR”). The intended facility is 16,000 square feet and the Corporation has been granted approval from Health Canada to build out the facility (“Ready to Build Letter”). After completing the construction of the facility as per the Ready to Build Letter the Corporation will schedule an inspection by Health Canada, and upon receiving approval the Corporation would then be granted a License to Produce.
Highmark and the Corporation are now negotiating the terms of the long form agreement, and pursuant to the Letter Highmark will issue 30,000 common shares to the Corporation.
The estimated cost of upgrading the facility to comply with the requirements set out in Health Canada’s Ready to Build letter is $2,000,000. The long form agreement will contain a payment schedule whereby Highmark will provide the necessary financing by way of a convertible loan which will convert, at Highmark’s option, into stock of the Corporation that will be equal to 51{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the total issued and outstanding shares of every class of the Corporation. Highmark intends to fund its commitments under the long form agreement with Corporation by way of an equity financing in the amount of $2,000,000.
The Corporation cannot legally become a producer under the MMPR until it has been granted a license, and it is not known if and when the Corporation will obtain a license. The key milestones to obtaining a license include the completion of upgrades to the facility as per the Ready to Build letter, approval from Health Canada to produce marijuana upon inspection of the facility, and finally approval to distribute the product to patients.
The Corporation has a management team well suited to the production of marijuana. One Co-Founder holds a Master Grower designation and was a producer of marijuana in the U.S.A. under a state sanctioned program, and he has more than 20 years’ experience working in the agricultural sector. Another Co-Founder has been a Health Canada designated grower of marijuana for 3 years, and another key member of the management team holds a Bachelor’s Degree in Economics and has a successful track record of managing a labour force of up to 40 employees.
The Corporation has presented Highmark a comprehensive five-year business plan in which it forecasts to reach profitability in the second year of operations after receiving Health Canada approval to become Licensed Producer. In that second year of operations, the Corporation is planning on sales of up to $472,000 per month, and obtaining $4,720,000 in annual sales, with a corresponding net income of $2,225,000.
Highmark intends on providing new information about the Corporation, and its assets when Due Dilligence permits, and will additionally update the status of the long form agreement when possible.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd. All rights reserved.
- Published in Medical Marijuana
46 Reasons why Cannabis Technologies (CAN) will Succeed
Cannabis Technologies has begun trading as InMed Pharmaceuticals (C.IN) since the writing of this article.
1) Investing in biotech can be extremely challenging. There is always a chance that someone will come out with a better product. Typically, it takes a decade or more to approval, followed by commercialization. It usuallycosts tens of millions, to billions of dollars per drug. This can be highly dilutive to a small startup.
2) What if one company had a proprietary cookie cutter system targeting a dozen diseases quicker, cheaper and more effective? I am not sure what Cannabis Technologies will be called in a year from now. I think it will have a new name… perhaps GW Pharmaceuticals or Eli Lily? Or Novartis?
3) Dr. Hossain was chiefly responsible for a $157 million deal with Novartis a decade ago. There was also a $376 million deal with Teva in 2012 based on one of his discoveries. More on that later.
4) Dr. Tarek Mansour (Pfizer) was responsible for multiple FDA approved drugs, where the market value exceeded $1 billion. (Zeffix, Troxatyl, Bosulif, Neratinib and PFE384)
5) The big question is...how many therapy product launches, and strategic partnerships will it take before Big Pharma catches on?
6) The amplitude of possibilities dictates that Cannabis Technologies will one day be a dominant player in the prescription cannabinoid medicine market.
7) Many people now know there are at least 85 different cannabinoids isolated from cannabis exhibiting various effects that could prove therapeutic.
8) They also know that cannabidiol (CBD) alone has shown therapeutic benefits to at least 16 diseases.
9) CAN will take advantage of Strain differences to develop drugs for specific diseases, including:
Glaucoma, Inflammation/Pain/Arthritis, Huntington’s, Epilepsy, Diabetes, Obesity, Cancer & Angiogenesis
10) CAN’s proprietary Cannabinoid Drug Design Platform (“CDP”) allows computer science, statistics, mathematics and engineering to study biological data and processes from the cannabis plant which can be targeted to develop therapies for specific diseases and conditions.
11) What will CAN’s CDP be worth to a company that wants to compete with GWPH…or a better question..what would it be worth to GWPH?
12) The main active ingredients in this are the cannabinoids THC and CBD, but other pharmacologically active cannabinoids are also present and are being investigated.
13) This Platform Technology, combined with CAN’s world renowned scientific team, will enable the company to discover therapies based on proven genomics and unique chemical fingerprints that specific cellular processes leave behind.
14) They will do this both quickly and effectively, with very little money, by outsourcing patented products that are ready for clinical trials and allow a company like Novartis (for example) to absorb all the costs through to commercialization. CAN will retain a fair and reasonable interest that may generate substantial revenue.
Track Record
Dr. Hossain’s successful financial deals based on his drug discoveries over the last 15 years include:
15) 2004: Xenon, Novartis Enter $157M Deal For Obesity Compounds
16) 2006: Xenon and Takeda Announce $75M Agreement To Develop and Commercialize XEN401 for Pain
17) 2006: Xenon Enters Into Anemia Collaboration With Roche ($7 Million for Equity, and $44 Million From Research Funding)
18) 2012: Teva inks $376M deal on Xenon pain program
19) 2009: YM Biosciences Collaboration with the National Research Council of Canada’s Biotechnology Research Institute (NRC-BRI) yielded novel anticancer antibodies that may be safer than similar drugs sold by Genentech/Roche. (another partnership resulted in the production of new breast cancer drug candidates.)
20) 2009: NRC-BRI granted Alethia Biotherapeutics exclusive, worldwide diagnostic rights to a peptide that specifically binds to tumor-associated clusterin in cancer patients.
Who should CAN target?
21) GW Pharmaceuticals has one the broadest clinical pipelines of any company in the marijuana industry…so will CAN.
22) Even though GW may be suffering the typical challenges that all biopharma companies have to endure, with costs far outstripping revenues, they had no problem raising $169.8 million last month.
23) Over 30 years ago, two young men made their way to Vancouver from Seattle to raise money for their software company, and were unfortunately turned down. Their names were Bill Gates and Paul Allen. Very few understood what they had.
24) I think CAN is in the same position today, however, that is changing with Chris Parry writing one of the first articles. Cancer survivor and canabis acdvocate Cheryl Shuman recently endorsed Cannabis Technologies as well.
25) If the billionaire activists want Marijuana to be legalized they most likely would want to facilitate the fast tracking of several revolutionary therapies that will indeed improve the lives of the millions of sufferers around the world.
26) George Soros has spent at least $80 million on the legalization effort since 1994.
27) The late Peter B. Lewis, channeled more than $40 million to influence local debates.
28) The two billionaires’ funding has been unmatched by anyone.
29) Other wealthy activists include: Google billionaire Paul Buchheit, Facebook forefathers Sean Parker and Dustin Moskovitz, and Men’s Wearhouse founder George Zimmer.
30) As of March 31, GWPH had 75 Institutional Holders (sooner or later, they will know about CAN)
31) Analyst Firms Making GWPH Recommendations: Bank of America, Cowen, Piper Jaffray, Leerink Swann, and Morgan Stanley.
Conclusion Check List:
32) World renowned scientific team with multidisciplinary expertise? Check.
33) CSO who has a track record that developed several drugs over 15 years, generating over $500m in revenues? Check
34) Global organizations, governments, and big pharma companies that have previously benefitted from the teams research? Check.
35) Proprietary Cannabinoid Drug Design Platform? Check.
36) Tools to isolate and identify chemical compounds both quickly and effectively? Check.
37) In-house Breeding, Genetics and Cultivation division? Check.
38) Capable of developing compounds for therapies in months rather than years? Check.
39) Target specific diseases and conditions? Check.
40) Outsource early-stage research and trials to conserve capital? Check.
41) Fast Forward through Phase I, Phase II & Phase III quickly and inexpensively compared to traditional Pharma? Check
42) Competitive edge from companies that rely on third-parties to manufacture their treatments? Check
43) Fully-integrated operations to lower costs and increase quality? Check
44) Capable of commercializing therapies in a 1/3 the time of traditional drug development? Check.
45) Anaglous company with a $1.5b market cap? Check
46) Developing medicines for:
– Glaucoma
– Pain and Inflammation
– Orphan Diseases
– Metabolic Disease (Obesity, Diabetes)
– Cancers and Metabolic Diseases? Check.
Dr. Sazzad Hossain, Ph.D., M.Sc.
Chief Scientific Officer
– 20 years of academic and industrial experience in new drug discovery, natural health product development
– Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada’s prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases.
Dr. Tarek S. Mansour, Ph.D., M.Sc.
Scientific Advisor
– Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline
-Founder and Chief Executive Officer of Sabila Biosciences LLC, New York
– Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development including:Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.
Dr. Hyder A. Khoja, Ph.D., M.Sc., A.Ag.
Director of Botanical Research and Cultivation
– 17 years of extensive experience in a broad range of life sciences and business services with strong leadership combined with functional expertise and experience in general business management
– Industry experience spans from initiation, operation, and contribution towards developing several research and business proposals in the fields of Agriculture-Food Security, Food Safety & Sovereignty, Alternative energy, Renewable resources, Biofuels, Nutraceutical, Hydroponics, Agriculture & Land use management and Technology transfer
– Presented his work both in at federal government and academic institutions with authorship in over 18 peer-reviewed papers, primarily in genomics, plant physiology, and alternative energy.
–His work was also recognized and appeared in United Nations Food and Agriculture Organization (FAO) Environment and Natural Resources Management as a working paper for Algae-based Biofuels
Craig Schneider
One of Craig’s first companies that he worked for was Ultra Petroleum. The stock dropped from .95 to .45 before blasting through the stratosphere to a stunning pre split price of close to $200. Put another way, the market cap rose from around $3 million to close to $3 Billion!
Loyal investors were rewarded once again in 2006, as he was the cofounder of Magnum Uranium, which was taken over by Energy Fuels in 2009. Shareholders were once again exposed to another potential 1000{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} gain by 2011.
Read more at http://www.stockhouse.com/companies/bullboard/c.can/cannabis-technologies-inc#2FOuXY6qmBPTVqry.99
- Published in Medical Marijuana
- 1
- 2